Sale disclosed
David Joseph Gaffin
EVP, CLO, Alkermes, Inc.
Ordinary Shares
- Reported value
- $83.46K
- Reported price
- $41.03 / share
Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…
Alkermes plc.
Last 30 daysNo qualifying insider buying. Sales: $83.46K by 1 insider.
Showing the first 6 of 19 trades on this page.
EVP, CLO, Alkermes, Inc.
Ordinary Shares
EVP, CLO, Alkermes, Inc.
Ordinary Shares
EVP R&D, Chief Medical Officer
Ordinary Shares
SVP, Chief Commercial Officer
Ordinary Shares
SVP, Chief Commercial Officer
Ordinary Shares
Director
Ordinary Shares
EVP R&D, Chief Medical Officer
Ordinary Shares
EVP, CLO, Alkermes, Inc.
Ordinary Shares
EVP, CLO, Alkermes, Inc.
Ordinary Shares
EVP R&D, Chief Medical Officer
Ordinary Shares
EVP R&D, Chief Medical Officer
Ordinary Shares
Director
Ordinary Shares
EVP, CLO, Alkermes, Inc.
Ordinary Shares
EVP R&D, Chief Medical Officer
Ordinary Shares
VP, Finance (Interim PAO)
Ordinary Shares
EVP, CLO, Alkermes, Inc.
Ordinary Shares
EVP R&D, Chief Medical Officer
Ordinary Shares
EVP, CLO, Alkermes, Inc.
Ordinary Shares
EVP R&D, Chief Medical Officer
Ordinary Shares
| Reporting insider | Security / transaction | Amount / price | Value | Traded / disclosed | Source |
|---|---|---|---|---|---|
| EVP, CLO, Alkermes, Inc. | Ordinary SharesSale10b5-1 | 2,034$41.03 / share | $83.46K | Oct 2Filed Oct 2 · 0d later | SEC filing |
| EVP, CLO, Alkermes, Inc. | Ordinary SharesSale10b5-1 | 2,034$48.01 / share | $97.65K | Sep 3Filed Sep 3 · 0d later | SEC filing |
| EVP R&D, Chief Medical Officer | Ordinary SharesSale10b5-1 | 9,000$46.99 / share | $422.87K | Sep 1Filed Sep 1 · 0d later | SEC filing |
| SVP, Chief Commercial Officer | Ordinary SharesSale10b5-12 trades | 7,576avg $49.23 / share | $372.94K | Aug 17Filed Aug 17 · 0d later | 2 filings
|
| Director | Ordinary SharesSale | 44,472$50.35 / share | $2.24M | Aug 3Filed Aug 3 · 0d later | SEC filing |
| EVP R&D, Chief Medical Officer | Ordinary SharesSale10b5-1 | 9,000$48.58 / share | $437.22K | Aug 3Filed Aug 3 · 0d later | SEC filing |
| EVP, CLO, Alkermes, Inc. | Ordinary SharesSale10b5-1 | 2,034$48.58 / share | $98.81K | Aug 3Filed Aug 3 · 0d later | SEC filing |
| EVP, CLO, Alkermes, Inc. | Ordinary SharesSale10b5-1 | 2,034$54.03 / share | $109.9K | Jul 6Filed Jul 6 · 0d later | SEC filing |
| EVP R&D, Chief Medical Officer | Ordinary SharesSale10b5-12 trades | 9,000avg $51.51 / share | $463.62K | Jul 1Filed Jul 1 · 0d later | 2 filings
|
| Director | Ordinary SharesSale10b5-1 | 2,000$45.10 / share | $90.2K | Jun 12Filed Jun 12 · 0d later | SEC filing |
| EVP, CLO, Alkermes, Inc. | Ordinary SharesSale10b5-1 | 2,034$43.05 / share | $87.56K | Jun 4Filed Jun 4 · 0d later | SEC filing |
| EVP R&D, Chief Medical Officer | Ordinary SharesSale10b5-1 | 9,000$41.67 / share | $375.04K | Jun 1Filed Jun 1 · 0d later | SEC filing |
| VP, Finance (Interim PAO) | Ordinary SharesSale | 16,217$42.36 / share | $687.01K | May 29Filed May 29 · 0d later | SEC filing |
| EVP, CLO, Alkermes, Inc. | Ordinary SharesSale10b5-1 | 2,034$33.20 / share | $67.53K | May 4Filed May 4 · 0d later | SEC filing |
| EVP R&D, Chief Medical Officer | Ordinary SharesSale10b5-1 | 9,000$33.40 / share | $300.56K | May 1Filed May 1 · 0d later | SEC filing |
| EVP, CLO, Alkermes, Inc. | Ordinary SharesSale10b5-1 | 2,034$34.57 / share | $70.32K | Apr 6Filed Apr 6 · 0d later | SEC filing |
| EVP R&D, Chief Medical Officer | Ordinary SharesSale10b5-1 | 9,000$35.51 / share | $319.6K | Apr 1Filed Apr 1 · 0d later | SEC filing |
Alkermes plc - Ordinary Shares (ALKS) · Stock
The filing reports a purchase for the member.
Gilbert CisnerosReporting House memberNo eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.
This score describes qualifying insider purchases at issuer level. Read the methodology
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.